Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 139, Issue , 2014, Pages 290-293

  Thelen, Paul ^a   Wuttke, Wolfgang ^b   Seidlová Wuttke, Dana ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Hormone and Obesity Center   (Germany)

Author keywords

Androgen receptor; Cancer prevention; Castration resistant prostate cancer (CRPC); Estrogen receptors; Hormone therapy; Phytoestrogens

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; ENZALUTAMIDE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ISOFLAVONE DERIVATIVE; ISOFLAVONOID; PHYTOESTROGEN; TECTORIGENIN; VALPROIC ACID;

ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DOWN REGULATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENE SILENCING; GOLD STANDARD; HUMAN; INFLAMMATION; LIGAND BINDING; LYMPH NODE METASTASIS; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; UBIQUITINATION;

ANDROGEN RECEPTOR; CANCER PREVENTION; CASTRATION RESISTANT PROSTATE CANCER (CRPC); ESTROGEN RECEPTORS; HORMONE THERAPY; PHYTOESTROGENS;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ESTROGEN RECEPTOR BETA; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHYTOESTROGENS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

EID: 84889884612     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.06.009     Document Type: Review

References (48)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 127 2010 2893 2917
2. M.M. Center, A. Jemal, J. Lortet-Tieulent, E. Ward, J. Ferlay, O. Brawley, and F. Bray International variation in prostate cancer incidence and mortality rates Eur. Urol. 61 2012 1079 1092
3. C. Huggins Effect of orchiectomy and irradiation on cancer of the prostate Ann. Surg. 115 1942 1192 1200
4. R.S. Rittmaster Chemoprevention of prostate cancer Acta Oncol. 50 Suppl. 1 2011 127 136
5. K.E. Knudsen, and H.I. Scher Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer Clin. Cancer Res. 15 2009 4792 4798
6. K.E. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol. Metab. 21 2010 315 324
7. K.K. Waltering, A. Urbanucci, and T. Visakorpi Androgen receptor (AR) aberrations in castration-resistant prostate cancer Mol. Cell Endocrinol. 360 2012 38 43
8. G.O. Hellawell, G.D. Turner, D.R. Davies, R. Poulsom, S.F. Brewster, and V.M. Macaulay Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease Cancer Res. 15 2002 2942 2950 (Pubitemid 34525783)
9. M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat. Rev. Cancer 12 2012 159 169
10. D. Mukherji, A. Eichholz, and J.S. de Bono Management of metastatic castration-resistant prostate cancer: recent advances Drugs 72 2012 1011 1028
11. M.D. Sadar Small molecule inhibitors targeting the achilles' heel of androgen receptor activity Cancer Res. 71 2011 1208 1213
12. T. Fixemer, K. Remberger, and H. Bonkhoff Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma Prostate 54 2003 79 87 (Pubitemid 36120323)
13. H. Bonkhoff, and R. Berges The evolving role of oestrogens and their receptors in the development and progression of prostate cancer Eur. Urol. 55 2009 533 542
14. G.S. Prins, L. Birch, J.F. Couse, I. Choi, B. Katzenellenbogen, and K.S. Korach Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice Cancer Res. 61 2001 6089 6097 (Pubitemid 32762544)
15. Z. Weihua, S. Makela, L.C. Andersson, S. Salmi, S. Saji, J.I. Webster, E.V. Jensen, S. Nilsson, M. Warner, and J.A. Gustafsson A role for estrogen receptor beta in the regulation of growth of the ventral prostate Proc. Natl. Acad. Sci. U.S.A. 98 2001 6330 6335 (Pubitemid 32492315)
16. R. Kumar, V. Verma, A. Jain, R.K. Jain, J.P. Maikhuri, and G. Gupta Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer J. Nutr. Biochem. 22 2011 723 731
17. N. Khan, V.M. Adhami, and H. Mukhtar Apoptosis by dietary agents for prevention and treatment of prostate cancer Endocr. Relat. Cancer 17 2010 R39 R52
18. E. Szliszka, and W. Krol Soy isoflavones augment the effect of TRAIL-mediated apoptotic death in prostate cancer cells Oncol. Rep. 26 2011 533 541
19. R.L. Jackson, J.S. Greiwe, and R.J. Schwen Emerging evidence of the health benefits of Sequol, an estrogen receptor β agonist Nutr. Rev. 69 2011 432 448
20. P. Pihlajamaa, F.P. Zhang, L. Saarinen, L. Mikkonen, S. Hautaniemi, and O.A. Jänne The phytoestrogen genistein is a tissue-specific androgen receptor modulator Endocrinology 152 2011 4395 4405
21. N. Miyanaga, H. Akaza, S. Hinotsu, T. Fujioka, S. Naito, M. Namiki, S. Takahashi, Y. Hirao, S. Horie, T. Tsukamoto, M. Mori, and H. Tsuji Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostatespecific antigen Cancer Sci. 103 2012 125 130
22. S. Nilsson, K.F. Koehler, and J.Å. Gustafsson Development of subtype-selective oestrogen receptor-based therapeutics Nat. Rev. Drug Discov. 10 2011 778 792
23. C. Schultz, M. Meier, and H.P. Schmid Nutrition, dietary supplements and adenocarcinoma of the prostate Maturitas 70 2011 339 342
24. H. Adlercreutz, H. Markkanen, and S. Watanabe Plasma concentrations of phytooestrogens in Japanese men Lancet 342 1993 1209 1210 (Pubitemid 23331713)
25. J.R. Hebert, T.G. Hurley, B.C. Olendzki, J. Teas, Y. Ma, and J.S. Hampl Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study J. Natl. Cancer Inst. 90 1998 1637 1647 (Pubitemid 28523438)
26. J. Zhang, I.B. Dhakal, Z. Zhao, and L. Li Trends in mortality from cancers of the breast, colon, prostate, esophagus and stomach in East Asia: role of nutrition transition Eur. J. Cancer Prev. 21 2012 480 489
27. P.L. de Souza, P.J. Russell, J.H. Kearsley, and L.G. Howes Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer Nutr. Rev. 68 2010 542 555
28. Y.W. Hwang, S.Y. Kim, S.H. Jee, Y.N. Kim, and C.M. Nam Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies Nutr. Cancer 61 2009 598 606
29. L. Gravitz Chemoprevention first line of defence Nature 471 2011 S5 S7
30. H.P. Schmid, C. Fischer, D.S. Engeler, M.L. Bendhack, and B.J. Schmitz-Dräger Nutritional aspects of primary prostate cancer prevention Recent Results Cancer Res. 188 2011 101 710
31. D. Seidlová-Wuttke, O. Hesse, H. Jarry, G. Rimoldi, P. Thelen, V. Christoffel, and W. Wuttke Belamcanda chinensis and the thereof purified tectorigenin have selective estrogen receptor modulator activities Phytomedicine 11 2004 392 403 (Pubitemid 38980519)
32. P. Thelen, J.G. Scharf, P. Burfeind, B. Hemmerlein, W. Wuttke, B. Spengler, V. Christoffel, R.H. Ringert, and D. Seidlová-Wuttke Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer Carcinogenesis 26 2005 1360 1367 (Pubitemid 41417878)
33. P. Thelen, T. Peter, A. Hünermund, S. Kaulfuss, D. Seidlová-Wuttke, W. Wuttke, R.H. Ringert, and F. Seseke Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells BJU Int. 100 2007 199 203 (Pubitemid 46878569)
34. S. Andres, K. Abraham, K.E. Appel, and A. Lampen Risks and benefits of dietary isoflavones for cancer Crit. Rev. Toxicol. 41 2011 463 506
35. E. Reiter, P. Gerster, and A. Jungbauer Red clover and soy isoflavones - an in vitro safety assessment Gynecol. Endocrinol. 27 2011 1037 1042
36. W. Wuttke, H. Jarry, S. Westphalen, V. Christoffel, and D. Seidlová-Wuttke Phytoestrogens for hormone replacement therapy? J. Steroid Biochem. Mol. Biol. 83 2002 133 147 (Pubitemid 37040650)
37. M. Messina Insights gained from 20 years of soy research J. Nutr. 140 2010 2289S 2295S
38. H. Wang, J. Li, Y. Gao, Y. Xu, Y. Pan, I. Tsuji, Z.J. Sun, and X.M. Li Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor Asian J. Androl. 12 2010 535 547
39. T.J. Walton, G. Li, R. Seth, S.E. McArdle, M.C. Bishop, and R.C. Rees DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines Prostate 68 2008 210 222 (Pubitemid 351186233)
40. I. Leav, K.M. Lau, J.Y. Adams, J.E. McNeal, M.E. Taplin, J. Wang, H. Singh, and S.M. Ho Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma Am. J. Pathol. 159 2001 79 92 (Pubitemid 33704195)
41. M. Stettner, S. Kaulfuss, P. Burfeind, S. Schweyer, A. Strauss, R.H. Ringert, and P. Thelen The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment Mol. Cancer Ther. 6 2007 2626 2633 (Pubitemid 350058143)
42. M. Göttlicher, S. Minucci, P. Zhu, O.H. Krämer, A. Schimpf, S. Giavara, J.P. Sleeman, F. Lo Coco, C. Nervi, P.G. Pelicci, and T. Heinzel Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J. 20 2001 6969 6978 (Pubitemid 34062289)
43. A.K. Sood, H. Kim, and J. Geradts PDEF in prostate cancer Prostate 72 2012 592 596
44. S.A. Wedel, A. Sparatore, P.D. Soldato, S.E. Al-Batran, A. Atmaca, E. Juengel, L. Hudak, D. Jonas, and R.A. Blaheta New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma J. Cell. Mol. Med. 12 2008 2457 2466
45. W. Weichert, A. Röske, V. Gekeler, T. Beckers, C. Stephan, K. Jung, F.R. Fritzsche, S. Niesporek, C. Denkert, M. Dietel, and G. Kristiansen Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy Br. J. Cancer 98 2008 604 610 (Pubitemid 351214528)
46. M. Sanchez, N. Picard, K. Sauvé, and A. Tremblay Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals Oncogene 32 2012 117 126
47. Y. Nakajima, K. Akaogi, T. Suzuki, A. Osakabe, C. Yamaguchi, N. Sunahara, J. Ishida, K. Kako, S. Ogawa, T. Fujimura, Y. Homma, A. Fukamizu, A. Murayama, K. Kimura, S. Inoue, and J. Yanagisawa Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5 Sci. Signal. 4 2011 ra22
48. J. Bouchal, F.R. Santer, P.P. Höschele, E. Tomastikova, H. Neuwirt, and Z. Culig Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer Prostate 71 2011 431 437